PT-179

• Description:

  PT-179 is an orthogonal Thalidomide (HY-14658) derivative that targets cereblon without causing off-target degradation effects. PT-179 is able to specifically bind CRBN, form a ternary complex with a target protein fused to a zinc finger (ZF) degron, and mediate the degradation of the tagged protein. For example, PT-179 binds to the ubiquitin ligase substrate receptor cereblon by forming a complex with SD40 and efficiently degrades proteins N- or C-terminally fused to SD40 or SD36 (DC50 for eGFP: 4.5 nM and 14.3 nM) . PT-179 can be used to develop compact protein degradation tagging platforms[1].

• UNSPSC:

  12352005

• Target:

  Ligands for E3 Ligase; Molecular Glues

• Type:

  Reference compound

• Related Pathways:

  PROTAC

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/pt-179.html

• Purity:

  99.91

• Solubility:

  DMSO : 125 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles:

  O=C1C2=CC=C(N3CCOCC3)C=C2C(N1C4C(NC(CC4)=O)=O)=O

• Molecular Formula:

  C17H17N3O5

• Molecular Weight:

  343.33

• References & Citations:

  [1]Mercer JAM, et al. Continuous evolution of compact protein degradation tags regulated by selective molecular glues. Science. 2024 Mar 15;383 (6688) :eadk4422.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  Cereblon

• CAS Number:

  [2924858-25-1]